Fresh off its $14 billion deal for Medivation--and in the midst of considering whether to split in two--Pfizer snapped up a portfolio of high-powered…

Pharma companies are discovering that developing apps and digital health technologies is just like developing drugs--at least when it comes to persuading…

Mylan has been pummeled by media, consumers, patients, pundits, politicians and even celebrities over charges of jacking up the price for its EpiPen auto…

Pharma ads may be ubiquitous during prime-time TV, but during the Olympic Games in Rio? Not so much. With $1.18 billion spent overall, pharma only accounted…

Big Pharma's emerging markets sales growth plunged to a new low last quarter. But within the group's overall average, some companies--such as…

The Attorney General in New York and some patients have filed suits against insurers that have balked at covering expensive hepatitis C drugs, while Medicaid…

Mylan is facing the prospect of investigations--as well as public criticism--following years of price increases on its big-selling EpiPen.

When one M&A door closes, many windows open. After Pfizer wrapped up a $14B Medivation buy Monday, investors bid up BioMarin, Incyte and more as likely…